background
although
sever
therapeut
option
becom
avail
patient
cutan
tcell
lymphoma
ctcl
therapi
cur
recent
studi
demonstr
ctcl
cell
overexpress
cc
chemokin
receptor
methodologyprincip
find
studi
xenograft
model
ctcl
establish
recombin
adenoassoci
viral
serotyp
vector
express
human
singlechain
variabl
fragment
scfv
fc
fusion
scfvfc
minibodi
monoclon
antibodi
mab
evalu
cur
treatment
human
tumorbear
mice
treat
intraven
infus
virion
encod
minibodi
show
antitumor
activ
vivo
increas
surviv
minibodi
notabl
increas
number
tumorinfiltr
fccriiia
murin
neutrophil
tumor
xenograft
minibodi
treat
mice
furthermor
tumorbear
mice
cotreat
minibodi
infus
human
peripher
blood
mononuclear
cell
pbmc
mark
tumor
infiltr
human
nk
cell
observ
minibodi
also
induc
vitro
adcc
activ
mous
neutrophil
human
nk
cell
conclusionssignific
overal
data
demonstr
vivo
antitumor
activ
minibodi
mediat
least
part
immun
effector
cell
adcc
mechan
data
demonstr
util
aavminibodi
gene
transfer
system
rapid
evalu
candid
antitumor
mab
potenc
potenti
novel
therapi
ctcl
cutan
cell
lymphoma
ctcl
clinic
heterogen
group
lymphoprolif
malign
character
clonal
accumul
matur
skinhom
memori
cell
mycosi
fungoid
mf
common
indol
form
ctcl
account
ctcl
case
primari
cutan
lymphoprolif
disord
specif
primari
cutan
anaplast
larg
cell
lymphoma
pcalcl
second
common
ctcl
account
circa
syndrom
aggress
leukem
variant
ctcl
affect
approxim
patient
patient
exhibit
signific
immun
dysfunct
global
dysregul
cell
due
unknown
etiolog
bacteri
sepsi
termin
event
patient
advanc
cancer
current
therapi
patient
advanc
ctcl
includ
leukem
variant
palli
extens
longterm
remiss
rare
poor
surviv
rate
patient
receiv
exist
therapi
clearli
emphas
need
develop
new
target
therapi
fatal
diseas
past
year
sever
studi
describ
express
chemokin
receptor
skin
blood
ctcl
patient
includ
uniformli
high
express
cc
chemokin
receptor
highli
express
leukem
ctcl
includ
syndrom
mf
earli
stage
patch
plaqu
stage
diseas
larg
cell
transform
also
express
circa
pcatcl
cell
recent
publish
consensu
articl
regard
classif
ctcl
clear
express
vast
major
ctcl
cell
regardless
histolog
subtyp
hand
express
limit
amongst
nonmalign
cell
present
neutrophil
monocyt
b
cell
absent
cell
present
fewer
half
memori
cell
express
tumor
cell
associ
skin
involv
also
import
role
normal
tumor
immun
express
high
level
regulatori
cell
treg
migrat
tumor
cell
secret
chemokin
facilit
evas
immun
surveil
high
express
ligand
detect
ctcl
lesion
breast
cancer
ovarian
cancer
oral
squamou
cell
carcinoma
thu
target
therapi
may
attract
treatment
option
malign
directli
kill
tumor
cell
also
overcom
suppress
effect
treg
host
antitumor
immun
respons
monoclon
antibodi
mab
base
immunotherapi
becom
standard
therapi
increas
number
human
cancer
tumor
target
human
mab
direct
tumorassoci
marker
might
provid
power
therapeut
strategi
ctcl
studi
use
recombin
adenoassoci
viral
aav
vectormedi
antibodi
gene
transfer
scidbeig
mice
evalu
effect
novel
human
mab
inhibit
tumor
cell
growth
increas
surviv
antibodi
gene
packag
aav
vector
deliv
singl
direct
intraven
iv
inject
lead
endogen
synthesi
durabl
express
therapeut
antibodi
level
month
intraven
deliveri
minibodyencod
aav
vector
allow
rapid
accur
assess
therapeut
potenti
therebi
avoid
ex
vivo
manipul
involv
product
purif
therapeut
mab
vivo
studi
use
therapeut
mab
gene
transfer
tumor
cell
implant
demonstr
potent
antitumor
activ
mab
addit
vivo
effector
cell
mediat
tumor
cell
kill
fc
bind
fcc
receptor
name
fccriiia
delin
studi
suggest
mab
serv
effect
antibodydirect
therapi
immunodeplet
malign
ctcl
cell
may
minim
collater
damag
alreadi
compromis
immun
system
furthermor
context
anticanc
mab
therapi
requir
frequent
repeat
administr
aavbas
therapeut
antibodi
gene
transfer
strategi
might
serv
altern
platform
deliveri
vitro
vivo
express
modifi
scfvfc
minibodi
format
use
antibodi
moieti
vector
v
domain
heavi
vh
light
vl
chain
human
scfv
fuse
code
region
hing
constant
domain
human
heavi
chain
yield
bival
bind
target
molecul
figur
dk
chang
et
al
press
result
recombin
vector
use
vitro
protein
synthesi
viru
product
vivo
antibodi
gene
deliveri
pilot
dose
studi
nude
mice
receiv
singl
inject
two
differ
concentr
via
intraven
tail
vein
inject
serum
minibodi
level
follow
week
minibodi
level
rose
first
week
reach
level
circa
ugml
low
vgmous
high
vgmous
vector
dose
respect
remain
week
studi
level
near
peak
level
high
dose
vector
circa
level
ugml
low
dose
vector
figur
vg
per
mous
gave
higher
serum
level
vector
concentr
use
subsequ
vivo
studi
tumor
cell
grow
well
scidbeig
mice
therefor
establish
xenograft
tumor
model
evalu
efficaci
therapeut
minibodi
gene
transfer
scidbeig
mice
treat
singl
intraven
tail
vein
inject
vector
timedepend
increas
serum
concentr
control
minibodi
reach
steadi
state
level
circa
ug
ml
day
remain
peak
level
day
last
day
studi
figur
control
irrelev
minibodi
direct
sar
spike
protein
determin
whether
transduct
vivo
could
result
product
properli
fold
scfvfc
protein
apurifi
minibodi
recov
serum
scidbeig
mice
three
week
follow
intraven
deliveri
vector
analyz
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
western
blot
shown
figur
examin
reduc
condit
minibodi
recov
vitro
vivo
sourc
show
band
expect
size
scfvfc
circa
kd
analysi
nonreduc
condit
show
dimer
format
mol
wt
circa
kd
therebi
confirm
minibodi
dival
vitro
vivo
figur
addit
eas
recoveri
minibodi
serum
use
affin
purif
protein
reactiv
western
blot
antihuman
fc
antibodi
stabl
dimer
format
confirm
proper
fold
structur
integr
domain
figur
bind
activ
minibodi
serum
follow
gene
transfer
determin
function
integr
scfvfc
minibodi
sera
obtain
mice
day
vivo
transduct
examin
level
bind
flow
cytometri
shown
figur
secret
minibodi
mous
serum
could
specif
bind
cell
cell
parent
cell
indic
scfv
domain
correctli
fold
retain
full
antigenbind
activ
irrelev
minibodi
serv
neg
control
bind
cell
therapeut
effect
gene
transfer
next
evalu
vivo
scidbeig
mice
carri
subcutan
implant
tumor
xenograft
group
mice
given
singl
intraven
inject
control
vector
day
tumor
inocul
tumor
volum
assess
twice
weekli
shown
figur
singl
inject
result
significantli
reduc
tumor
growth
compar
treat
mice
pb
control
treat
mice
day
day
mous
surviv
monitor
month
tumorbear
mice
treat
significantli
outliv
mice
treat
untreat
mice
figur
sinc
scidbeig
mice
lack
b
lymphocyt
well
function
natur
killer
nk
cell
possibl
tumor
cell
elimin
neutrophildepend
adcc
neutrophil
intact
scidbeig
mice
express
fccriiia
receptor
shown
mediat
adcc
tumor
section
excis
day
gene
transfer
analyz
histolog
express
member
famili
glycosylphosphatidylinositol
gpi
anchor
protein
express
murin
neutrophil
immunostain
tumor
section
neutrophilspecif
mab
confirm
infiltr
neutrophil
tumor
treat
figur
upperleft
middl
panel
figur
lowerleft
right
panel
quantif
neutrophil
infiltr
demonstr
mark
accumul
stain
cell
treat
mice
figur
assess
mous
neutrophildepend
tumor
cell
kill
vitro
adcc
assay
carri
use
purifi
scidbeig
mous
neutrophil
minibodi
cocultur
cell
mous
neutrophil
presenc
effector
target
ratio
result
signific
neutrophilmedi
adcc
measur
lactat
dehydrogenas
ldh
releas
cell
figur
control
minibodi
abl
induc
neutrophilmedi
cytotox
vitro
result
correl
observ
antitumor
activ
vivo
suggest
antitumor
activ
minibodi
ctcl
murin
model
mediat
least
part
fcc
receptor
iiia
engag
mous
neutrophil
induc
adcc
effector
function
therapeut
ctcl
model
extend
evalu
role
human
effector
cell
tumor
cell
kill
use
bioluminesc
imag
bli
luciferas
express
cell
establish
retrovir
transduct
ten
scidbeig
mice
graft
cell
develop
equival
size
tumor
detect
day
bli
divid
two
group
eleven
day
initi
tumor
cell
inocul
vector
administ
intraven
next
human
pbmc
hpbmc
given
intraperiton
inject
day
aav
vector
administr
shown
figur
treatment
hpbmc
result
substanti
tumor
growth
inhibit
compar
plu
hpbmc
treat
mice
quantit
monitor
tumor
growth
vivo
bli
correl
visibl
tumor
growth
confirm
tumor
growth
inhibit
effect
compar
control
group
figur
signific
differ
observ
control
therapeut
group
day
tumor
inocul
calip
measur
day
bli
figur
b
realtim
wholebodi
bli
repres
mous
show
tumor
growth
consider
inhibit
mice
treat
compar
control
mice
treatment
period
figur
analysi
microcomput
tomographypositron
emiss
tomographi
mctpet
imag
also
reveal
tumor
growth
inhibit
treatment
compar
control
group
show
primari
tumor
growth
day
tumor
inocul
tumor
cell
becam
much
local
invas
treat
group
show
increas
metabol
activ
indic
accumul
pet
tracer
ffluorodeoxyglucos
fdg
wholebodi
imag
mice
figur
assess
vivo
mechan
tumor
cell
kill
plu
human
pbmc
treat
group
role
human
nk
cell
also
express
fccriiia
receptor
evalu
treatment
group
substanti
increas
tumorinfiltr
human
nk
cell
observ
shown
intens
immunostain
compar
control
treat
mice
figur
quantit
color
deconvolut
analysi
show
significantli
increas
stain
mous
group
treat
compar
control
group
treat
figur
human
nk
cellmedi
adcc
activ
also
evalu
vitro
use
purifi
human
nk
cell
effector
cell
shown
figur
human
nk
cell
abl
kill
target
cell
presenc
dose
depend
fashion
control
minibodi
show
low
level
kill
mous
neutrophil
human
nk
cell
express
fccriiia
receptor
surfac
bind
vitro
vivo
data
strongli
support
mediat
kill
occur
least
part
fccriiia
engag
activ
immun
cell
effector
function
studi
therapeut
antibodi
gene
transfer
model
develop
evalu
novel
human
monoclon
antibodi
therapeut
drug
candid
ctcl
scidbeig
mice
use
establish
ctcl
model
lack
b
cell
function
nk
cell
high
level
durabl
express
minibodi
achiev
singl
intraven
inject
signific
antitumor
activ
cell
seen
two
anim
treatment
studi
result
provid
first
vivo
evid
mab
may
clinic
activ
ctcl
cell
suggest
studi
undertaken
investig
clinic
efficaci
remark
among
find
studi
singl
intraven
tail
vein
treatment
minibodi
result
dose
depend
increas
serum
minibodi
level
steadili
increas
two
week
period
remain
near
peak
level
end
week
studi
figur
figur
integr
minibodi
demonstr
biochem
vitro
vivo
sever
paramet
includ
bind
activ
stabl
dimer
format
eas
recoveri
protein
chromatographi
figur
c
scfvfc
minibodi
format
may
ideal
experiment
deliveri
sinc
convent
mab
express
deriv
heavi
light
chain
gene
difficult
achiev
balanc
express
two
gene
within
singl
aav
vector
small
packag
capac
less
kb
although
selfprocess
peptid
furin
cleavag
success
use
drive
express
fulllength
rat
igg
cancer
immunotherapi
scfvfc
minibodi
appear
promis
shown
function
compar
fulllength
igg
success
use
treat
variou
tumor
preclin
studi
ad
benefit
along
bival
antigenbind
avid
intact
antibodi
effector
function
compris
singl
polypeptid
chain
requir
balanc
heavi
light
antibodi
chain
heterocomplex
associ
smaller
molecular
weight
better
tissu
penetr
compar
whole
igg
molecul
function
integr
minibodi
also
shown
potent
vivo
antitumor
vitro
kill
activ
first
treatment
studi
model
mark
inhibit
tumor
cell
growth
increas
surviv
seen
figur
b
even
though
scidbeig
mice
profound
immun
cell
defect
includ
lack
b
cell
well
impair
macrophag
nk
cell
effector
function
ihc
stain
paraffinembed
tumor
tissu
reveal
predomin
infiltr
neutrophil
minibodi
control
minibodi
treat
mice
figur
furthermor
vitro
adcc
assay
use
purifi
mous
neutrophil
effector
cell
demonstr
induc
signific
lysi
cell
lysi
seen
figur
result
support
view
neutrophilmedi
adcc
involv
antitumor
activ
follow
gene
deliveri
scidbeig
ctcl
mous
model
therapeut
scidbeig
ctcl
model
extend
evalu
role
human
effector
cell
tumor
cell
kill
second
treatment
studi
model
gene
deliveri
togeth
human
pbmc
evalu
signific
inhibit
tumor
cell
growth
seen
figur
therapeut
effect
monitor
use
tumor
size
measur
bli
comparison
measur
tumor
volum
bli
analysi
enabl
earlier
tumor
detect
reveal
extens
cell
death
respons
treatment
figur
addit
micropet
ct
imag
provid
threedimension
analysi
primari
tumor
evalu
effect
treatment
vivo
pet
imag
indic
invas
tumor
cell
infiltr
surround
tissu
seen
treat
mice
figur
fccriiia
receptor
domin
fccr
involv
human
nk
cellmedi
adcc
treatment
tumor
bear
mice
human
pbmc
result
mark
increas
number
tumorinfiltr
human
nk
cell
suggest
express
human
nk
cell
involv
tumor
cell
kill
interact
fc
portion
find
experiment
confirm
fc
mutagenesi
studi
data
shown
moreov
vitro
adcc
studi
purifi
human
nk
cell
demonstr
concentr
depend
kill
figur
thu
unifi
observ
treatment
studi
strongli
suggest
vivo
antitumor
activ
mediat
least
larg
part
adcc
engag
fccriiia
mous
neutrophil
model
human
nk
cell
model
sinc
fc
gamma
receptor
fccr
differ
type
present
varieti
effector
cell
popul
includ
nk
cell
dendrit
cell
macrophag
monocyt
neutrophil
possibl
fccr
engag
immun
effector
cell
investig
studi
could
also
involv
mab
therapi
advanc
ctcl
propos
numer
trial
alemtuzumab
shown
modest
moder
clinic
effect
recent
trial
low
dose
alemtuzumab
shown
complet
remiss
patient
refractori
leukem
form
diseas
without
infecti
diseas
complic
although
found
complet
ineffect
treatment
mf
mab
genmab
design
orphan
drug
treatment
mf
fda
approach
design
elimin
ctcl
cell
signific
advers
effect
either
treatment
express
virtual
b
cell
elimin
cell
wellknown
neg
consequ
clonal
malign
cell
ctcl
patient
express
uniformli
high
level
variabl
low
level
skin
home
addressin
includ
cla
also
uniformli
highli
express
leukem
variant
ctcl
cm
phenotyp
express
phenotyp
em
cell
found
mf
skin
lesion
thu
uniformli
express
form
ctcl
restrict
express
pattern
normal
cell
includ
treg
inde
subset
malign
cell
ctcl
shown
act
treg
suppress
antitumor
respons
may
fuel
diseas
progress
therapeut
mab
could
preferenti
target
form
diseas
revers
treg
mediat
immun
suppress
would
major
advanc
effect
therapi
ctcl
activ
abrog
treg
mediat
suppress
effector
cell
function
describ
elsewher
dk
chang
et
al
press
mab
anoth
human
mab
shown
promis
result
ctcl
anim
studi
clinic
trial
refractori
adult
tcell
leukemia
atll
peripher
cell
lymphoma
plcl
good
clinic
activ
without
sever
advers
side
effect
seen
data
support
explor
clinic
potenti
therapeut
mab
target
ctcl
summari
result
present
studi
valid
util
therapeut
minibodi
gene
transfer
platform
rapid
experiment
evalu
mab
treatment
human
cancer
furthermor
studi
show
minibodi
inhibit
primari
tumor
burden
suppress
local
metastasi
prolong
surviv
time
tumorbear
scidbeig
mice
remain
hope
addit
studi
support
human
move
bench
bedsid
human
skintrop
anaplast
largecel
lymphoma
alcl
cell
line
origin
isol
laboratori
marshal
e
kadin
harvard
medic
school
cultur
rpmi
medium
supplement
fetal
bovin
serum
fb
mm
mgml
immunophenotyp
cell
line
show
express
known
tumorspecif
chemokin
receptor
includ
high
level
cell
line
stabli
transduc
luciferas
encod
retroviru
hek
cell
cultur
dulbecco
modifi
eagl
medium
supplement
fb
penicillinstreptomycin
invitrogen
cell
cultur
maintain
co
humidifi
incub
human
pbmc
obtain
danafarb
blood
center
purifi
ficollhypaqu
densiti
gradient
centrifug
describ
gener
protocol
miltenyi
biotec
inc
auburn
ca
mous
neutrophil
isol
scidbeig
mous
blood
percol
densiti
gradient
centrifug
describ
human
nk
cell
isol
human
pbmc
use
nk
cell
isol
kit
accord
manufactur
protocol
miltenyi
biotec
ca
construct
scfvfc
minibodi
express
cassett
scfvfc
gene
pcramplifi
plasmid
code
human
antihuman
antibodi
deriv
heavi
light
antibodi
chain
mab
r
system
inc
previous
clone
laboratori
dk
chang
et
al
press
insert
aavclon
vector
ptruf
obtain
univers
iowa
viral
vector
core
restrict
site
consequ
effici
direct
express
secret
singl
chain
mab
ptruf
vector
modifi
insert
human
igg
leader
sequenc
fc
sequenc
hing
domain
human
flank
termin
repeat
itr
figur
recombin
viral
vector
produc
use
helper
virusfre
system
modif
lowpassag
human
hek
cell
cotransfect
linear
polyethylenimin
polysci
three
plasmid
aav
cisplasmid
ptruf
encod
human
mab
gene
express
cassett
flank
itr
aavpackag
plasmid
contain
rep
cap
gene
ad
helper
plasmid
contain
va
rna
gene
requir
aav
propag
obtain
dr
jim
wilson
univers
pennsylvania
h
posttransfect
cell
harvest
aav
viru
extract
freez
thaw
cell
subsequ
aav
purifi
two
sequenti
iodixanol
densiti
gradient
concentr
desalt
centrifug
biomax
filter
millipor
accord
manufactur
instruct
viral
titer
determin
genom
copi
titer
vg
quantit
realtim
pcr
use
primer
probe
speicif
aav
vector
ptruf
forward
primer
locat
end
revers
primer
begin
invert
termin
repeat
itr
probe
famtamra
locat
larger
quantiti
aav
serotyp
vector
encod
scfvfc
control
minibodi
specif
sar
scfvfc
produc
harvard
gene
therapi
initi
harvard
institut
medicin
boston
use
anim
studi
mice
monitor
tumor
develop
progress
calib
measur
xenogen
bli
latter
initi
monitor
tumor
growth
day
tumor
implant
repeat
week
mice
anesthet
isofluran
induct
chamber
follow
intraperiton
administr
mgml
dluciferin
imag
mice
maintain
isofluran
anesthesia
deliv
nose
cone
whole
bodi
imag
repeatedli
acquir
maximum
peak
photon
number
confirm
variou
exposur
time
min
data
quantifi
use
time
point
gave
highest
photon
number
scan
time
analyz
use
live
imag
softwar
calip
life
scienc
hopkinton
petct
scan
perform
harvard
medic
school
imag
core
facil
mice
fast
h
ffdg
inject
provid
water
ad
libitum
ffdg
inject
imag
mice
anesthet
use
isofluran
anim
intraperiton
inject
mbq
mci
ffdg
allow
regain
conscious
kept
imag
imag
start
min
intraperiton
inject
mice
imag
chamber
minim
posit
error
pet
ct
less
mm
imag
acquisit
time
min
imag
analyz
use
amid
softwar
region
interest
defin
fuse
petct
imag
ensur
reproduc
posit
hek
cell
atcc
manassa
va
transfect
aavcod
plasmid
contain
minibodyexpress
construct
use
lipofectamin
invitrogen
carlsbad
ca
three
day
transfect
minibodi
purifi
supernat
protein
sepharos
affin
chromatographi
vivo
product
gener
iv
inject
scidbeig
mice
describ
level
minibodi
serum
measur
duplic
use
human
igg
elisa
quantit
kit
accord
manufactur
protocol
bethyl
laboratori
inc
montgomeri
tx
western
immunoblot
perform
protein
column
purifi
sampl
contain
vitro
synthes
minibodi
vivo
minibodi
protein
separ
sdspage
reduc
nonreduc
condit
electrophoret
transfer
onto
nitrocellulos
membran
use
iblot
dri
blot
system
invitrogen
block
skim
milk
overnight
blot
probe
apconjug
human
iggfc
antibodi
dilut
block
buffer
h
room
temperatur
excess
conjug
remov
five
wash
phosphat
buffer
salin
contain
tween
pbst
detect
protein
perform
incub
membran
bcipnbt
alkalin
phosphatas
substrat
kpl
biolog
activ
vivo
minbodi
analyz
fluorescenceactiv
cell
sort
fac
bind
activ
cell
cell
wash
pb
supplement
bovin
serum
albumin
pbsb
incub
vivo
produc
h
room
temperatur
follow
incub
antihuman
iggfc
conjug
fluorescein
isothiocyan
fitc
flow
cytometr
analysi
perform
use
bd
facscalibur
bd
bioscienc
san
jose
ca
flowjo
data
analysi
softwar
tree
star
inc
ashland
immunohistochem
stain
perform
dfciharvard
cancer
center
research
patholog
core
qualit
quantit
immunohistochem
analysi
formalinfix
paraffinembed
tissu
section
stain
antibodi
direct
surfac
mous
neutrophil
human
antigen
human
nk
cell
stain
slide
scan
use
aperio
imagescop
aperio
technolog
inc
vista
ca
full
tumor
section
select
quantit
analys
percentag
posit
stain
cell
entir
tumor
section
calcul
use
color
deconvolut
algorithm
vitro
antibodydepend
cell
cytotox
assay
adcc
perform
use
lactat
dehydrogenas
ldh
releas
assay
method
accord
nonradioact
cytotox
assay
procedur
specifi
manufactur
promega
madison
wi
mous
neutrophil
purifi
scidbeig
mous
purifi
human
nk
cell
pbmc
use
effector
cell
tumor
cell
use
target
cell
briefli
purifi
scidbeig
mous
neutrophil
nk
cell
plate
densiti
cell
per
well
roundbottom
plate
presenc
minibodi
h
incub
freshli
prepar
effector
cell
ad
effectortarget
cell
ratio
e
mous
neutrophil
human
nk
cell
h
incub
supernat
well
recov
centrifug
min
ldh
activ
supernat
determin
measur
absorb
wavelength
nm
cytotox
calcul
accord
follow
formula
e
ldh
releas
effectortarget
cocultur
se
spontan
releas
ldh
effector
cell
st
spontan
releas
ldh
target
cell
maximum
releas
ldh
target
cell
incub
lysi
solut
tritonx
measur
done
triplic
statist
analys
perform
use
anova
bonferroni
post
hoc
test
unpair
ttest
use
graphpad
prism
graphpad
softwar
inc
la
jolla
ca
p
valu
less
consid
statist
signific
figur
dose
depend
express
minibodi
nude
mice
mice
per
group
treat
one
time
tail
vein
inject
viral
vector
two
concentr
show
pb
buffer
treat
mice
serv
control
mice
bled
indic
time
point
week
scfvfc
level
determin
elisa
antihuman
ig
captur
detect
tif
